Himmelreich G, Hundt K, Bechstein W O, Rossaint R, Neuhaus P, Riess H
Department of Internal Medicine, University Clinic Rudolf Virchow, Berlin, Germany.
Semin Thromb Hemost. 1993;19(3):273-8. doi: 10.1055/s-2007-994039.
In the control group, a significant decrease in platelet aggregability could be demonstrated after reperfusion. This was paralleled by a decrease in platelet counts. When PGE1 was infused during OLT, the post-reperfusional decreases in platelet aggregability and platelet counts in the control group could be prevented. Furthermore, our investigation demonstrated that PGE1 infusion led to higher t-PA activity during the anhepatic phase. This was paralleled and followed by lower alpha 2AP levels at the end of the anhepatic phase and after reperfusion. The higher t-PA levels in the PG group did not result in clinical signs of hyperfibrinolysis during OLT. The aprotinin administration in both groups is most certainly responsible for the absence of hyperfibrinolytic signs in the TEG and the low overall requirement for transfusions, explaining the comparable transfusion rate in the two groups (Fig. 5). Further investigations involving more patients are required to evaluate the clinical effect of PGE1 therapy.
在对照组中，再灌注后可证实血小板聚集性显著降低。这与血小板计数的减少同时出现。当在肝移植术中输注PGE1时，可防止对照组再灌注后血小板聚集性和血小板计数的降低。此外，我们的研究表明，输注PGE1会导致无肝期t-PA活性升高。这与无肝期末期和再灌注后较低的α2AP水平同时出现并随之出现。PG组较高的t-PA水平在肝移植术中并未导致高纤溶的临床体征。两组中使用抑肽酶最肯定是导致血栓弹力图中无高纤溶体征以及输血总体需求量低的原因，这解释了两组中相似的输血率（图5）。需要涉及更多患者的进一步研究来评估PGE1治疗的临床效果。
